What is LifeSprout?
Founded in 2015 by a distinguished cohort of scientists and surgeons from Johns Hopkins University, LifeSprout operates at the intersection of biotechnology and reconstructive surgery. The company specializes in the development of innovative soft tissue restoration products designed to replicate the structural and functional properties of human tissue. By focusing on high-growth sectors such as aesthetic enhancement and reconstructive medicine, LifeSprout addresses critical clinical needs with a portfolio that emphasizes patient safety, minimal recovery time, and superior physiological integration. Their market position is defined by a commitment to rigorous scientific validation and the translation of academic breakthroughs into scalable, commercial-grade medical devices.
How much funding has LifeSprout raised?
LifeSprout has raised a total of $35.1M across 3 funding rounds:
Angel/Seed
$6.5M
Debt
$150K
Series A
$28.5M
Angel/Seed (2019): $6.5M with participation from Triskelion Investments, Maryland Technology Development Corporation, Ginkgo Gofar, Angel MD, Medytox, Inc., and Kairos Venture Partners
Debt (2020): $150K led by PPP
Series A (2020): $28.5M supported by Abell Foundation Inc, Nexus Management Inc, Redmile Group , LLC, and emeraldmanagers.com
Key Investors in LifeSprout
Maryland Technology Development Corporation
TEDCO is a Maryland-based organization that provides funding, resources, and connections to early-stage technology and life sciences companies, fostering innovation and entrepreneurship.
Kairos Venture Partners
A venture capital firm that partners with world-class scientists and engineers to commercialize breakthrough technologies originating from top-tier research institutions.
Redmile Group, LLC
An investment firm focused on the healthcare sector, providing strategic capital to companies developing transformative medical therapies and technologies.
What's next for LifeSprout?
With the recent influx of capital, LifeSprout is well-positioned to accelerate its clinical development pipeline and expand its commercial footprint. The company's strategic roadmap likely involves scaling manufacturing capabilities to meet anticipated demand for its restorative product suite while navigating the complex regulatory landscapes of the aesthetic and reconstructive sectors. As the firm transitions from early-stage development to a more mature commercial entity, the focus will remain on securing long-term clinical efficacy data and establishing strategic partnerships to broaden market access. This phase of growth is critical for LifeSprout to solidify its reputation as a provider of best-in-class regenerative solutions, ultimately aiming to redefine standards of care in soft tissue management.
See full LifeSprout company page
